Ivabradine Krka

Active Ingredient:: Ivabradine
Origin:: EU

Ivabradine Krka (Ivabradine)

Q: What conditions is Ivabradine Krka used for?

Ivabradine Krka is prescribed to lower heart rate in adults with chronic stable angina and in patients with chronic heart failure with reduced ejection fraction (NYHA class II‑III). By slowing the sinus node, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Q: How does ivabradine work to treat these conditions?

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Blocking this current reduces the rate of depolarisation, leading to a controlled decrease in resting heart rate without affecting myocardial contractility.

Q: What is the usual dose of Ivabradine Krka?

The appropriate dose of Ivabradine Krka is determined by the prescribing clinician based on the patient’s heart‑rate, clinical status and concomitant therapies. Dosage adjustments are made according to therapeutic response and tolerability.

Q: Is Ivabradine Krka safe to use during pregnancy or breastfeeding?

The safety of Ivabradine Krka in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

Q: How do I order Ivabradine Krka from GNH India?

To request Ivabradine Krka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does ivabradine compare with beta‑blockers for heart‑rate control?

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If channel without affecting blood pressure or myocardial contractility. Beta‑blockers have broader cardiovascular effects, including reduction of contractility and blood pressure, which may be advantageous or limiting depending on the patient’s overall condition.

Q: What are the recommended storage conditions for Ivabradine Krka?

Ivabradine Krka tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children.

Q: How is Ivabradine Krka administered?

Ivabradine Krka is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

Q: What are the most serious risks associated with Ivabradine Krka?

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Q: Who should not use Ivabradine Krka?

Ivabradine Krka is contraindicated in patients with severe hypotension (systolic BP <90 mmHg), acute decompensated heart failure, unstable angina, sick sinus syndrome, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Ivabradine, the active ingredient in Ivabradine Krka, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to treat chronic stable angina and chronic heart failure with reduced ejection fraction in adult patients.

GNH India supplies Ivabradine Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Krka, D.D., Novo Mesto

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ivabradine acts on the cardiac If current to manage conditions where heart‑rate reduction improves outcomes.

Chronic stable angina: improves exercise tolerance and reduces frequency of angina attacks.
Chronic heart failure with reduced ejection fraction (NYHA class II‑III): lowers heart rate, alleviates symptoms and may decrease hospitalisations.
Heart failure (NYHA class II‑III) with reduced ejection fraction: contributes to better functional capacity and quality of life.

How It Works

Ivabradine selectively binds to the funny (If) current channels in the sinoatrial node, inhibiting the inward sodium/potassium flow that drives spontaneous depolarisation. This action slows the pacemaker activity, producing a dose‑dependent reduction in resting heart rate without affecting myocardial contractility or intracardiac conduction.

Side Effects

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Luminous phenomena (phosphenes): transient visual disturbances.
Bradycardia: heart rate below the intended therapeutic range.
Headache.
Dizziness.
Fatigue.
Blurred vision.

Serious or Rare Side Effects

Symptomatic bradycardia requiring medical intervention.
Atrial fibrillation or other arrhythmias.
Severe hypotension.
Allergic reactions including rash or angioedema.
Visual disturbances persisting beyond transient phosphenes.
Myocardial ischaemia in susceptible patients.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient suitability and monitor for potential risks.

Heart rate monitoring: ensure resting heart rate remains above 50 bpm.
Avoid in severe hypotension: contraindicated when systolic blood pressure is <90 mmHg.
Caution in hepatic impairment: dose adjustment may be required.
Do not use in acute decompensated heart failure or unstable angina.
Contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Ivabradine can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole): increase ivabradine plasma levels.
Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction.
Certain anti‑arrhythmic drugs (e.g., amiodarone) that affect cardiac conduction.

Moderate Interactions (Monitor Closely)

Moderate CYP3A4 inhibitors (fluconazole, erythromycin): may modestly raise ivabradine concentrations.
CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): may reduce therapeutic effect.
Antihypertensive agents (ACE inhibitors, ARBs): monitor blood pressure for additive hypotensive effect.
Other anti‑anginal drugs (nitrates, ranolazine): assess for combined symptom control and side‑effect profile.

Frequently Asked Questions

Ivabradine Krka is prescribed to lower heart rate in adults with chronic stable angina and in patients with chronic heart failure with reduced ejection fraction (NYHA class II‑III). By slowing the sinus node, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which is responsible for spontaneous pacemaker activity. Blocking this current reduces the rate of depolarisation, leading to a controlled decrease in resting heart rate without affecting myocardial contractility.

The appropriate dose of Ivabradine Krka is determined by the prescribing clinician based on the patient’s heart‑rate, clinical status and concomitant therapies. Dosage adjustments are made according to therapeutic response and tolerability.

The safety of Ivabradine Krka in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Ivabradine Krka, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine acts selectively on the If channel without affecting blood pressure or myocardial contractility. Beta‑blockers have broader cardiovascular effects, including reduction of contractility and blood pressure, which may be advantageous or limiting depending on the patient’s overall condition.

Ivabradine Krka tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children.

Ivabradine Krka is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed.

The most serious risks include symptomatic bradycardia, atrial fibrillation, severe hypotension, and persistent visual disturbances. Patients should be monitored for these events, especially when initiating therapy or adjusting the dose.

Ivabradine Krka is contraindicated in patients with severe hypotension (systolic BP <90 mmHg), acute decompensated heart failure, unstable angina, sick sinus syndrome, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to ivabradine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 14 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.